The minimally invasive nature of liquid biopsy tests and the array of different tumor information provided by these tests are expected to attract the patients with higher purchasing power and fuel the innovations and market growth.
According to a report published by Allied Market Research, the global liquid biopsy market is estimated to reach $3.80 billion by 2023 registering a CAGR of 28.9% during the period 2017–2023. Liquid biopsy has benefitted the healthcare and therapeutic research sectors with its accuracy and molecular aspects. Most importantly, it is non-invasive, cost-effective, and less painful, which has proved to be a miracle treatment for cancer patients. It provides the cancer profile at an early stage and guides the doctors and physicians to follow an appropriate therapy, improving the survival rate of the cancer patients. Liquid biopsy can also be used for rare forms of cancer. Other than that, the surge in the global prevalence of cancer is another contributing factor providing growth to the global liquid biopsy market. However, with scientific advancements, researchers are learning more regarding the potential of liquid biopsy to detect mutations. Thus, the future is expected to be revolutionary for sure.
The number of patients suffering from cancer have escalated drastically within last few years. While observing a tumor or lump in a patient, the first step doctors take is to perform tissue biopsy in pinpoint any indications of cancer. Tissue biopsy is a process to collect body cells for microscopic analysis for better understanding of the disease. The microscopic analysis of the cells can determine whether the disease is cancer or not. Moreover, it can illustrate its type and provide further information regarding the patient’s prognosis. Furthermore, it can help to modify the treatment strategy. However, tissue biopsy involves a large needle, an endoscope, and sometimes an open surgery, which could be painful, costly, and a bit risky.
Tissue biopsy has been a difficult process as it was uncomfortable for patients and may include innate clinical risks, potential surgical complications, and economic concerns. Furthermore, some tumors are not easily accessible for tissue biopsy as the patients may have various health conditions. Apart from this, tissue biopsy cannot be recommended to those patients who are going through antiangiogenic treatment. Such issues make it difficult to perform frequent biopsies in intervals on a patient. Since tumors get developed over time, performing this procedure could bring more discomfort. Nevertheless, this process helps to detect and find information regarding the type of and development cancer.
Download Sample Copy of this Report @ https://www.alliedmarketresearch.com/request-sample/1891
Liquid biopsy to be less painful, cost-efficient, and convenient for cancer patients:
Liquid biopsy revolutionized the way of diagnosing and treating cancer. It is an alternative for tissue biopsy that can analyze tumors with the help of bodily fluids, including blood, urine, and saliva. Liquid biopsy is a non-invasive method of diagnosing and monitoring cancer-related information with the help of biological markers. Previously various liquid biopsy tests included analysis of several kinds of tumor materials including DNA, RNA, proteins, and exosomes.
A liquid biopsy can provide genetic information of all cancer-related lesions and offer opportunities to methodically track enlarging genomes. The tests can detect molecules that favor cancer in patients with the help of samples of bodily fluids such as blood, saliva cerebrospinal fluid, and urine. Moreover, biopsies provide the histological definition of the disease in cancer patients and expose details regarding the genetic outline of the tumor to predict the evolution of the disease in the patient’s body and response to therapies.
Liquid biopsy provides information regarding the further development of cancer in a patient’s body and offers opportunities to improve the survival rate of the cancer patient. It can be used to predict the chances of the disease returning after completing the treatment.
Detecting circulating tumor DNA-based biopsies to detect cancer at an early stage:
Liquid biopsy has been tested to analyze tumor DNA in the blood– ctDNA. The ctDNA-based liquid biopsies are vital to detect cancer at an early stage, as it offers an additional time for the essential treatment to be successful. In some cases, liquid biopsies detected ctDNA in blood samples of patients earlier compared to other conventional method of diagnosis.
Check available discounts on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/1891
Liquid biopsy is useful for frequent tests as it can guide the doctors regarding the development of the tumors. As some tumors are slow-growing and less or not at all harming, operating it might prove to be harmful and risky. Moreover, liquid biopsies provide an advanced understanding regarding evolving metastatic sites, recognizing tumors, and detecting the rate of cancer development in a patient.
One of the major advantages of ctDNA-based liquid biopsy is that they are useful for examining the patient’s responses to the therapy, during and after the treatment. Since it is non-invasive and easily repetitive, it can help clinicians to track the responses to understand what adjustments should be made in the course of treatment.
What’s more, a liquid biopsy provides inclusive imagery of all the cancerous indication in a patient’s body. Unlike tissue biopsy, liquid biopsy informs about the entire body and not just about the cancer-infected area. Liquid biopsy has proved effective for the patients suffering from metastatic gastrointestinal (GI) cancers, as it has presented rare alterations, guiding the doctors to treat accordingly. Liquid biopsy has changed the way of treating cancer over other conventional procedures. Furthermore, it can be used for treating rare type of cancers. Moreover, with further developments and improved therapies, liquid biopsy will garner more attention and would be widely accepted to treat cancer patients.
The key players analyzed in the report include
- Biocept, Inc
- Hoffmann-La Roche AG
- Bio-Rad Laboratories Inc
- Myriad Genetics
Liquid Biopsy Market Key Findings:
- Hospital & laboratory segment was the highest revenue-generating segment, and is expected to continue its dominance in future
- North America dominated global liquid biopsy market, and is projected to grow at a CAGR of 28.1%.
- The government & academic research center segment is projected to grow at the highest rate during the analysis period.
- China is expected to grow at the highest CAGR of 34.1% in Asia-Pacific region.
- The instruments segment is anticipated to grow at the highest CAGR of 29.8% during the forecast period.
Scope of the Report
|Market size available for years||2017-2023|
|Base year considered||2018|
|Forecast units||Value (USD)|
|Segments covered||Type, Product & Service|
|Geographies covered||North America, Europe, Asia-Pacific, LAMEA|
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060